Format

Send to

Choose Destination
Curr Opin Ophthalmol. 2018 Jul;29(4):360-364. doi: 10.1097/ICU.0000000000000483.

Management of herpes simplex virus epithelial keratitis.

Author information

1
Cornea Service, Wills Eye Hospital, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.

Abstract

PURPOSE OF REVIEW:

To review recent advancements in the management of herpes simplex virus (HSV) epithelial keratitis.

RECENT FINDINGS:

Trifluridine eye drop, acyclovir (ACV) ointment, ganciclovir gel, and oral ACV are still the main therapeutic agents. Cryopreserved amniotic membrane has been recently used as an adjuvant treatment. Resistance to ACV has become a concerning issue. The animal models of HSV vaccine are able to reduce HSV keratitis. New antivirals are under development.

SUMMARY:

Current cases of HSV epithelial keratitis are manageable with available medications, but new advancements are required to decrease disease burden in the future. HSV vaccine can be revolutionary.

PMID:
29697435
DOI:
10.1097/ICU.0000000000000483
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center